Prevention of transplant rejection: Current treatment guidelines and future developments

Drugs

Volumn 54, Issue 4, 1997, Pages 533-570

  Perico, Norberto ^a   Remuzzi, Giuscppe ^a,b  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FINGOLIMOD; HLA ANTIGEN CLASS 1; IMMUNOSUPPRESSIVE AGENT; INOSINATE DEHYDROGENASE; INTERLEUKIN 2; LYMPHOCYTE ANTIBODY; LYMPHOCYTE ANTIGEN; MIZORIBINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; RAPAMYCIN; TACROLIMUS; TERIFLUNOMIDE;

ALLOGRAFT; APOPTOSIS; BONE NECROSIS; CELL CYCLE; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG MECHANISM; GENE THERAPY; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCYTE PROLIFERATION; META ANALYSIS; MICROEMULSION; MULTICENTER STUDY; NATURAL KILLER CELL; NEPHROTOXICITY; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PRACTICE GUIDELINE; PURINE SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0030659494     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754040-00003     Document Type: Review

References (320)

1. Colvin R. Cellular and molecular mechanisms of allograft rejection. Annu Rev Med 1990; 41: 361-75
2. Sayegh M, Watschinger B. Carpenter C. Mechanisms of T cell recognition of alloantigen: role of peptides. Transplantation 1994; 57: 1295-302
3. Steinman R, Young J, Signals arising from antigen-presenting cells. Curr Opin Immunol 1991; 3: 361-72
4. Schwartz R. Acquisition of immunologic self-toleranee. Cell 1989; 57: 1073-81
5. June C, Ledheller J, Linsley P, et al. Role of the CD28 receptor in T-cell activation. Immunol Today 1990; 11: 211-6
6. Hitchings GH, Elion GB. The role of antimetaholites in immunosuppression and transplantation. Ace Chem Res 1964; 2: 202-12
7. Elion GB. The pharmacology of azathioprine. Ann N Y Acad Sci 1443; 685: 401-7
8. St Georgiev V. Enzymes of the purine metabolism: inhibition and therapeutic potential, Ann N Y Acad Sci 1993; 685: 207-16
9. Mitchell BS, Dayton JS, Turka LA. et al. IMP dehydrogenase inhibitors as immunomodulators. Ann N Y Acad Sci 1943; 685: 217-24
10. de Mattos AM, Olyaci AJ, Bennett WM. Pharmacology of immunosuppressivo medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28: 631-67
11. Hitchings OH, Elion GB. Chemical immunosuppression of the immune response. Pharmacol Rev 1963; 15: 365-401
12. MeGeown MG, Kennedy JA, Loughridge WG. et al. One hundred kidney transplants in the Belfast City Hospital. Lancet 1477; 11: 648-51
13. Papadakis J, Brown CB, Cameron JS. et al. High versus 'low' dose corticosteroids in recipients of cadaveric kidneys: prospective controlled trial. BMJ 1983; 286: 1097-100
14. Salaman JR, Griffin PJA, Price K. A controlled clinical trial of low-dose prednisolono in renal transplantation, Transplant Proc 1982; 14: 103-6
15. Chan L, French ME, Beare J. et al. Prospective trial of high-dose versus low dose prednisone in renal transplant patients. Transplant Proc 1980; 12: 323-6
16. Chan L, French ME, Oliver DO. et al. High and low dose prednisone. Transplant Proc 1481; 13: 336-8
17. Calne RY, White DJ, Thuru S. et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1478; 11: 1323-7
18. Calne R, Rolles K, White D. et al. Cyclosporin A initially as the only immunosuppressant in 36 recipients of cadaveric organs: 32 kidneys. 2 pancreas, and 2 livers. Lancet 1974; 11: 1033-6
19. Calne R, White D. The use of cyclosporin A in clinical organ grafting. Ann Surg 1482; 196: 330-7
20. Starzl T, Klintmalm G, Weil RI. et al. Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients, Surg Gynecol Obstet 1981; 153: 486-94
21. Rosenthal J, HakalaT, Iwatsuki S. et al. Cadaveric renal transplantation under cyclosporine-steroid therapy. Surg Gynecol Obstet 1983; 157: 309-15
22. Simmons R, Canafax D, Strand M. Management and prevention of cyclosporine nephroloxicity after renal transplantation: use of low dose of cyclosporine, azathioprine. and prednisone. Transplant Proc 1485; 17: 266-75
23. First M, Alexander J, Wodhwa N. The use of low doses of cyclosporine. azathioprine and prednisone in renal transplantation. Transplant Proc 1986; 18: 132-5
24. Collaborative Transplant Study. Newsletter 4 1992 Nov
25. Simmons RL, Canafax DM, Strand M. et al. Management and prevention of cyclosporine nephrotoxicity after renal transplantation: use of low doses of cyclosporine, azathioprine, and prednisone. Transplant Proc 1985; 17 Suppl. 1: 266-75
26. Under R, Lindholm A, Restifo A. et al. Long-term renal allograft function under maintenance immunosuppression with cyclosporine Aorazathioprine. Transplant Int 1991; 4: 166-72
27. Perico N, Remuzzi G. Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplant Rev 1991; 5: 63-80
28. Myers BD, Ross J, Newton L. et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705
29. Lowson DH, Lovatt GE, Gurton CS. et al. Adverse effects of azathioprine. Adverse Drug React Acute Poisoning Rev 1984; 3: 161-71
30. Penn I. The changing pattern of posttransplant malignancies, Transplant Proc 1991; 23: 1101-3
31. Hricik DE, O'Toole MA, Schulak JA. et al. Steroid-free immunosuppression in cydosporine-treated renal transplant recipients; a meta-analysis. J Am Soc Nephrol 1993; 4: 1300-5
32. Kupin W, Venkat KK, Heung K. et al. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Transplantation 1988; 45: 53-5
33. Hricik DE, Lautman J, Bartucci MR. et al. Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. Transplantation 1992; 53: 1232-5
34. Pirsch JD, Armburst MJ, Knechtle SJ. et al. Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. Transplant Proc 1991; 23: 1363-4
35. Hricik DE, Bartucci MR, Mayes JT. et al. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868-71
36. Hricik DE, Bartucci MR, Moir EJ. et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cydosporine-treated renal transplant recipients, Transplantation 1991; 51: 374-7
37. Albert FW, Schmidt U. Cyclosporine therapy with or without steroids in cadaveric kidney transplantation - a prospective randomized one-center study. Transplant Proc 1987; 17: 2669-70
38. Johnson RWG, Mallick NP, Bakran A. et al. Cadaver renal transplantation without maintenance steroids. Transplant Proc 1989; 21: 1581-2
39. Sinclair NR, for the Canadian Multicentre Transplant Study Group. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. Can Med Assoc J 1992; 147: 645-55
40. Opelz G, Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994; 58: 443-6
41. Ratcliffe PJ, Dudley CRK, Higgins RM. et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosupprcssion. Lancet 1996; 348: 643-8
42. Hricik DE, Whalen CC, Lautman J. et al. Withdrawal of steroid after renal transplantation - clinical predictors of outcome. Transplantation 1992; 53: 41-5
43. Cristinelli L, Brunori G, Setti G. et al. Withdrawal of methylprednisolone at the sixth month in renal transplant recipients treated with cyclosporine. Transplant Proc 1987; 19: 2021-3
44. Mason J. Cyclosporines past, present, and future. Transplant Proc 1992; 24 Suppl. 4: 61-3
45. Kahan B, Cydosporine. N Engl J Med 1989; 321: 1725-38
46. Canadian Multicentre Transplant Study Group. A rundomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1986; 314: 1219-25
47. Starzl T, Klintmalm G, Porte K. et al. Liver transplantation with use of cyclosporine A and prednisone. N Engl J Med 1981; 305: 266-9
48. Macoviak J, Oyer P, Stinson E. et al. Four-year experience with cyclosporine for heart und heart-lung transplantation. Transplant Proc 1985; 17 Suppl. 2: 97-101
49. Traeger J, Dubernard J, Pozza G. Influence of immunosuppressive therapy on the endocrine function of segmental pancreatic allografts. Transplant Proc 1983; 15: 1326-8
50. Feutren G, Querin S, Chatenoud L. et al. The effects of cyclosporine in twelve patients with severe systemic lupus. In: Schindler R. editor. Cyclosporine in autoimmune diseases. New York: Springer-Verlag. 1985: 366-72
51. Schreiber S. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283-7
52. Fruman D, Burakoff S, Bierer B. Immunophilins in protein folding and immunosuppression. FASEB J 1994; 8: 391-400
53. Liu J, Farmer J, Lane W. et al. Calcincurin is a common target of cyclophilin-cyclosporin A and FK506-FKBP complexes, Cell 1991; 66: 807-15
54. Fruman D, Klee C, Bierer B. et al. Calcineurin phosphatase in T lymphocytes is inhibited by FK506 and cyclosporine A. Proc Natl Acad Sci USA 1992; 89: 3686-90
55. Klintmalm G, Sawe J, Ringden O. et al. Cyclosporine plasma levels in renal transplant patients: association with renal toxicity and allograft rejection. Transplantation 1985; 39: 132-7
56. Lindholm A, Kahan B. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-18
57. Burke J, Pirsch J, Ramos E. et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994; 331: 358-63
58. Grevel J, Welsh M, Kahan B. Cyclosporine monitoring in renal transplantation: area under the curve monitoring is superior to trough level monitoring. Ther Drug Monil 1989; 11: 246-89
59. Kivisto K. A review of assay methods forcyclosporin: clinical implications. Clin Pharmacokinet 1992; 23: 173-90
60. Kahan B, Shaw L, Holt D. et al. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990; 36: 1510-6
61. Shaw L. Advances in cyclosporine pharmacology, measurement, and therapeutic monitoring. Clin Chem 1989; 35: 1299-308
62. Perna A, Gotti E, de Bernardis E. et al. A logistic-regression model provides novel guidelines to maximize the anti-acute rejection properties of cyclosporine with a minimum of toxicity, J Am Soc Nephrol 1996; 7: 786-91
63. Basadonna G, Matas A, Gillingham K. et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993-5
64. Salomon D, Brunson M, Vansickler J. et al. A retrospective analysis of late renal graft function: correlation with mean cyclosporine levels and lack of evidence for chronic cyclosporine toxicity. Transplant Proc 1991; 23: 1018-9
65. Nankivell B, Hibbins M, Chapman J. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994; 58: 989-96
66. Gaspari F, Ruggenenti P, Torre L. et al. Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney Int 1993; 44: 436-9
67. Holt D, Mueller E, Kovarik J. et al. The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclospurine. Transplant Proc 1994; 25: 2935-9
68. Kovarik J, Mueller E, Johnston A. et al. Bioequivalence of soft gelatin capsules and oral solution of a new cyclosporine formulation, Pharmacotherapy 1993; 13: 613-7
69. The Canadian Neoral Study Group. A randomized prospective multicentre pharmacoepidemiologic study of Neoral (cyclosporine microemulsion) in stable renal graft recipients [abstract]. American Society Transplant Physicians: 15th Annual Meeting; 1996 May 26-30; Dallas (TX), 170
70. Amante A, Lindholm A, Welsh M. et al. Cyclosporine pharmacokinetic risk factors for acute rejection episodes in renal transplantation [abstract]. American Society of Transplant Physicians; 15th Annual Meeting; 1996 May 26-30; Dallas (TX), 118
71. Uaspari F, Anedda MF. Signorini O. et al. Prediction of cyclosporine area under the curve using a three point sampling strategy after Neoral administration. J Am Soc Nephrol 1997; 8: 647-52
72. Serafinowicz A, Gaciong Z, Baczkowska T. et al. Limited sampling strategy to estimate exposure to CsA in renal allograft recipients (RARs) trented with Sandimmun-Ncoral (NEO) (abstract), 2nd International Conference on New Trends in Clinical and Experimental Immunosuppression; 1996 Feb 13-16; Geneva, 59
73. Riradori A, Martinez L, Eldberg A. et al. Preliminary pharmacokinetic evaluation of a new galenic formulation of oral cyclosporine A: Neoral. Transplant Proc 1995; 27: 1813-4
74. Mueller HA, Kovarik JM, van Bree JB. et al. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients - a concentration-controlled comparison with the commercial formulation. Transplantation 1994; 57: 1178-82
75. Steinmuller D, Dougherty J, Coutee J. et al. The effect of conversion from Sandimmun to Neoral on glomerular filtration rate in stable renal transplant recipients [abstract], XVI International Congress of the Transplantation Society; 1996 Aug 25-30: Barcelona, 283
76. Ricart MJ, Andreu J, Oppenheimer F, et al. Acute renal failure after renal transplantation under various immunosuppressive regimens. Transplant Proc 1988; 20: 36-7
77. Carpenter BJ, Rosenthal JT, Taylor RJ. The impact of acute tubular necrosis on graft outcome in patients receiving cyclosporine. Transplant Proc 1985; 17: 1282-3
78. Canafax DM, Torres A, Fryd DS. et al. The effects of delayed function on recipients of cadaver renal allografts. Transplantation 1986; 41: 177-81
79. Cho SI, Zalneraitis BP, Franklin C. The influence of acute tubular necrosis on kidney transplant survival. Transplant Proc 1985; 17: 16-7
80. Weimar W, Hendriks GFJ, Wenting GJ. et al. Prophylactic antilymphocyte globulin and HLA-DR matching reduce the incidence of rejection after cadaveric kidney transplantation. Transplant Proc 1987; 19: 3612-3
81. Sommer BG, Henry M, Ferguson RM. Sequential antilymphoblast globulin and cyclosporine for renal transplantation. Transplantation 1987; 43: 85-90
82. Kupin WL, Venkatachalam KK, Oh HK. et al. Sequential use of Minnesota antilymphoblast globulin and cyclosporine in cadaveric renal transplantation. Transplantation 1985; 40: 601-4
83. Freis D, Hiesse C, Charpentier B. et al. Optimal results in cadaveric renal transplantation with low-dose cyclosporine and steroids combined with prophylactic anti-lymphocyte globulin. Transplant Proc 1988; 20 Suppl. 6: 23-5
84. Hiesse C, Fries D, Charpentier B. et al. Optimal results in cadaver-donor renal transplantation using prophylactic ALG, cyclosporine, and prednisone. Transplant Proc 1987; 19: 3670-1
85. Nestor ZT, Rocher LL, Merion RM. et al. Peri-operative antilymphoblast globulin (ALG) and delayed initiation of cyclosporine (CsA) diminishes the requirement for prolonged dialysis therapy after renal transplantation. Transplant Proc 1989; 21: 1556-7
86. Gaston RS, Hudson SL, Deierhoi MH. et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation 1992; 53: 103-9
87. Stratta RJ, D'Alessandro AM, Armbrust MJ. et al. Sequential antilymphocyte globulin/cyelosporine immunosuppression in cadaveric renal transplantation. Transplantation 1989; 47: 96-102
88. Norman D, Shield C, Barry J. et al. Early use of OKT3 monoclonal antibody in renal transplantation to prevent rejection. Am J Kidney Dis 1988; 9: 107-10
89. Norman D, Kahana L, Stuart FJ, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44-50
90. Canadian Multicentre Transplant Study Group. A randomised clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1986; 314: 1219-25
91. Belitsky P, MacDonald AS, Cohen AD. et al. Comparison of antilymphocyte globulin and continuous IV cyclosporine A as induction immunosuppression for cadaver kidney transplants: a prospective randomized study. Transplant Proc 1991; 23: 999-1000
92. Johnson CP, Simmons RL, Sutherland DER, et al. A randomized trial comparing cyclosprorine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Transplantation 1988; 45: 380-5
93. Michael HJ, Francos GC, Burke JF. et al. A comparison of the effects of cyclosporine versus antilymphocytc globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 1989; 48: 805-8
94. Slakey DP, Johnson CP, Callaluce RD. et al. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function. Transplantation 1993; 56: 827-31
95. Abouna GM, Al-Ahdullah IH, Kelly-Sullivan D. et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with adjustment according to T cell monitoring. Transplantation 1995; 59: 1564-8
96. Kung P, Goldstein G, Reinherz EL. et al. Monoclonal antibodies defining human T cell surface antigens. Science 1979; 206: 347-9
97. Chang TW, Kung PC, Gingras SP. et al. Does OKT3 monoclonal antibody react with an antigen-recognition structure on human T cells'? Proc Natl Acad Sci USA 1981; 78: 1805-8
98. van der Elsen P, Shepley BA, Borst J. et al. Isolation of cDN A clones encoding the 20K T3 glycoprotein of human T-cell receptor complex. Nature 1984; 312: 413-8
99. Todd PA, Brogden RN. Muromonab CD3: a review of its pharmacology and therapeutic potential. Drugs 1989; 37: 871-99
100. Hanto DW, Jendrisak MD, So SKS. et al. Induction immunosuppression with antilymphocyle globulin or OKT3 in cadaver kidney transplantation. Transplantation 1994; 57: 377-84
101. Cohen DJ, Benevenisly AI, Cianci J. et al. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function. Am J Kidney Dis 1989; 14 Suppl. 2: 19-27
102. Grino JM, Castelao AM, Seron D. et al. Antilymphocyte globulin OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study. Am J Kidney Dis 1992; 20: 603-10
103. Swinnen JL, Costanzo Nordin MR, Fisher SG. et al. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal OKT3 in cardiac transplant recipients. N Engl J Med 1990; 323: 1723-8
104. Peterson PK, Balfour HH, Fryd DS. et al. Fever in renal transplant recipients: causes, prognostic significance and changing patterns at the University of Minnesota Hospital. Am J Med 1981; 71: 345-51
105. Rao KV, Kasiske BL, Bloom PM. Acute graft rejection in the late survivors of renal transplantation: clinical and histological observations in the second decade. Transplantation 1989; 47: 290-2
106. Kincaid-Smith P, McKenzie IF, Morris PJ. et al. Biopsy features of early acute rejection in cadaveric renal grafts. Transplant Proc 1969; 1: 287-9
107. Waltzer WC, Miller F, Arnold A. et al. Value of percutaneous core needle biopsy in the differential diagnosis of renal transplant dysfunction. J Urol 1987; 137: 1117-21
108. Tanaka H, Kuroda A, Marusawa H. et al. Structure of FK506: a novel immunosuppressant isolated from streptomyces. J Am Chem Soc 1987; 109: 5031-3
109. Venkataramanan R, Jain A, Warty V. et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991; 23: 2736-40
110. Yoshimura N, Oka T. FK506, a new immunosuppressive agent: a review. J Immunol Immunopharmacol 1990; 10: 32-6
111. Northrop JP, Ho SN, Chen L. et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 1994; 369: 497-502
112. Todo S, Fung JJ, Tzakis AJ. et al. One hundred ten consecutive primary orthotopic liver transplants under FK506 in adults. Transplant Proc 1991; 23: 1397-1402
113. Fung J, Abu-Elmagd K, Jain A. et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine. Transplant Proc 1991; 23: 2977-83
114. US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-5
115. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-8
116. Starzl TE, Donner A, Eliasziw M. et al. Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet 1995; 346: 1346-50
117. Steinmuller DR. FK506 and organ transplantation. Austin (TX): RG Landes Co., 1994
118. van Hooff J. The European prospective randomised trial comparing tacrolimus and cyclosporin in the prevention of renal allograft rejection [abstract], XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 45
119. FK506 US Kidney Transplant Multicenter Study Group. FK506 in kidney transplantation: results of the U. S. randomized, comparative, phase III study [abstract). XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona. 45
120. Mathew A, Talbot D, Minford E. et al. Reversal of steroid-resistant rejection in renal allograft recipients using FK506. Transplantation 1995; 60: 1182-4
121. Woodle ES, Thistlethwaite Jr JR, Gordon JH. et al. A prospective, multicenter trial of FK 506 (tacrolimus) therapy for refractory acute renal allograft rejection |abstract]. XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 46
122. Jordan ML, Naraghi R, Shapiro R. et al. Tacrolimus rescue therapy for renal allograft rejection - five year experience [abstract]. XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona. 46
123. Jordan ML, Naraghi R, Shapiro R. et al. Tacrolimus rescue therapy for renal allograft rejection - five years experience. Transplantation 1997; 63; 223-8
124. Wang SC, Morel PA, Wang Q. et al. A dual mechanism of immunosupppression by FK506: differential suppression of IL4 and IL-10 levels in T helper 2 cells. Transplantation 1993; 56: 978-85
125. Gjertson DW, Cecka JM, Terasaki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995; 60: 1384-8
126. Wang T, Donahoe P, Zervos A. Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP12. Science 1994; 265: 674-6
127. Franklin T, Cook J. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969; 113: 515-24
128. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug. mycophenolate mofetil. Immunol Rev 1993; 136: 5-28
129. Platz. KP, Sollinger HW, Hullert DA. et al. RS-61443; a new, potent immunosuppressive agent. Transplantation 1991; 51: 27-31
130. Allison A, Eugui E. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993; 7: 96-112
131. Sollinger H. Mycophenolate mophetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-32
132. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosternids for prevention of acute rejection. Lancet 1995; 345: 1321-5
133. Halloran P. A pooled analysis of three randomized double-blind clinical studies in prevention of rejection with mycophenolate mofelil in renal allograft recipients (the 1-year analysis) |abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May; Dallas (TX), 166
134. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-37
135. Kirklin JK, Bourge RC, Naftel DC. et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994; 13: 444-50
136. Taylor DO, Ensley D, Olsen SL. et al. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 1994; 13: 571-82
137. Shaffer D, Madras P, Sayhoun A. et al. Mycophenolate Mofetil eliminates the rationale for antilymphocyte induction therapy in non-haploidentical living donor kidney transplants, [abstract], XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 176
138. Morris R, Hoyt E, Murphy M. et al. Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. Transplant Proc 1990; 22: 1659-62
139. Platz K, Sollinger H, Hullett D. et al. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991; 51: 27-35
140. Sollinger H, Belzer F, Deierhoi M. et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992; 216: 513-8
141. Mycophenolale Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722-9
142. Mizuno K, Tsujino M, Takada M. et al. Studies on bredinin: I. Isolation, characterization and biological properties. J Antibiol Tokyo. 1474; 27: 775-82
143. Sakaguchi K, Tsujino M, Hayashi M. et al. Mode of action of bredinin with guanylic acid on L5178Y mouse leukemia cells. J Antibiol Tokyo 1976; 29: 1320-7
144. Turka LA, Dayton J, Sinclair G. et al. Ouanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 1991; 87: 9411-8
145. Uchida M, Yokota K, Akiyama N. et al. Effectiveness of a new drug, bredinin, on canine kidney allotransplant survival, Transplant Proc 1979; 11: 865-70
146. Kokado Y, Ishibushi M, Jiang H. et al. Low-dose cyclosporin mizoribine and prednisolone in renal transplantation: a new triple-drug therapy. Clin Transplant 1990; 4: 191-7
147. Mita K, Akiyama N, Nagao T. et al. Advantages of mizoribine over azathioprine in combination therapy with cyclosporine for renal transplantation. Transplant Proc 1990; 22: 1679-81
148. Sonda K, Takahushi K, Tanabe K. et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patienis. Transplant Proc 1996; 28: 3643-8
149. Teraoka S, Toma H, Nihei H. et al. Current status of renal replacement therapy in Japan. Am J Kidney Dis 1995; 25: 151-64
150. Gruber SA, Erdmann GR, Burke BA. et al. Mizoribine pharmacokinetics and pharmacodynamics in a canine renal allograft model of local immunosuppression. Transplantation 1992; 53: 12-9
151. Vezina G, Kudelski A, Sehgal S, Rapamycin (AY-22.989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28: 721-6
152. Sigal NH, Dumont FJ, Cyclosporin A, FK-506, and rapamycin: pharmacologic probes of lymphocyte signal transduction. Ann Rev Immunol 1992; 10: 519-60
153. Camardo JS, Scarola JA, Maida BT. Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hypertens 1995; 4: 482-7
154. Morris R, Rapamycins: antifungal, antitumor. antiproliferative. and immunosuppressive macrolides. Transplant Rev 1992; 6: 39-87
155. Cardenas ME, Xhu D, Heitman J, Molecular mechanisms of immunosuppression by eyelosporine. FK506. and rapamycin. Curr Opin Nephrol Hypertens 1995; 4: 472-7
156. Granger DK, Cromwell JW, Chen SC. et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monothersipy. Transplantation 1995; 59: 183-6
157. Kahan B. Katz S, Jordan S. et al. Sirolimus permits rapid corticosteroid withdrawal from a cyclosporine-based regimen in renal transplantation [abstract|. American Society of Transplant Physicians, 15th Annual Meeting; 1996 May: Dallas (TX). 165
158. Brattstrom C, Sawe J, Tyden G. et al. Two randomized, douhle-blind. placebo-controlled studies to determine safety, tolerance and pharmacokinetics of ascending single doses of orally administered Sirolimus (rapamycin) in stable renal transplant recipients and healthy male volunteers [abstract]. XVI Inter- national Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona. 76
159. Kahan BD, Pescovitz M, Julian B. et al. Multi-center phase II trial of Sirolimus (SRL) in renal transplantation: six-months results |abstract|. XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 75
160. Neylan JF, Pescovitz MD, Julian BA. et al. Multi-center phase II trial of Sirolimus in renal transplantation: Immunosuppressive requirements for black patients [abstract], XVI International Congress of the Transplantalion Society; 1996 Aug 25-30; Barcelona. 75
161. Vanrenterghem Y, Pescovitz MD, Kahan BD. et al. Infectious complications in the multi-center phase II trial of Sirolimus and Cyclosporine in renal transplantation [abstract]. XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona. 77
162. Murgia MG, Jordan S, Kahan BD, The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients, Kidney Int 1996; 49: 209-16
163. Kahan BD, Katz, SM, Jordan SM. et al. Sirolimus permits rapid corlicosteroid withdrawal from a cyclosporine-based regimen in renal transplantation (abstract). XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 76
164. Morris R, Cao W, Huang X. et al. Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis. Transplant Proc 1445; 27: 2068-9
165. Wasowska B, Hancock W, Onodera K. et al. Rapamycin plus cyclosporin A a novel regimen to prevent chronic allograft rejection in sensitised hosts [abstract]. American Society of Transplant Physicians 15th Animal Meeting: 1996 May 26-30: Dallas (TX). 120
166. Platt J, LeBien T, Michael A, Interstitial mononuclear cell populations in renal graft rejection: identification by monoclonal antibodies in tissue sections. J Exp Med 1982; 155: 17-30
167. Hall B, Bishop G, Farnsworth A. et al. Identification of the cellular subpopulations infiltrating rejection cadaver renal allografts: preponderance of the T4 subset of T cells. Transplantation 1484; 37: 564-70
168. Pober J, Cotran R, The role of endothelial cells in inflammation, Transplantation 1990; 50: 537-44
169. Heemann U, Tullius S, Kupiec-Weglinski J. et al. Early events in acute allograft rejection: leukocyte/endothelial cell interactions. Clin Transplantation 1943; 7: 82-4
170. van Seventer G, Shimzu Y, Shaw S. Roles of multiple accessory molecules in T-cell activation. Curr Opin Immunol 1941; 3: 294-303
171. Springer T, Adhesion receptors of the immune system. Nature 1990; 346: 425-34
172. Isobe M, Yagita H, Ukumura K. et al. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-I and LFA-1. Science 1992; 255: 1125-7
173. Cosimi A, Conti D, Delmonico K. et al. In vivo effects of monoclonal antibody to ICAM-I (CD54) in nonhuman primates with renal allografts. J Immunol 1990; 144: 4604-12
174. Haug C, Colvin R, Delmonico F. et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantalion 1993; 55: 766-73
175. Kulz S, Phan T, Bennett C. et al. Perioperative treatment with ICAM-1 antisense oligonucleotide in panereatic islet transplantation [abstract] American Society of Transplant Physi- cians 15th Annual Meeting; 1996 May 26-30: Dallas (TX). 159
176. Katz S, Browne B, Phan T. et al. ICAM-1/LFA-1 blockade improves islet allograft survival and function [abstract]. XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 201
177. Katz S, Browne B, Phan T. et al. ICAM-1/LFA-1 blockade improves islet allograft survival and function [abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May 26-30; Dallas (TX), 158
178. Stepkowski S, Wang M, Amante A, et al. Antisense intracellular adhesion molecule-1 (ICAM-1) oligodeoxynucleotidc blocks allograrft rejection in rat and monkey models [abstract], XVI International Congress of the Transplantation Society: 1996 Aug 25-30; Barcelona, 112
179. Stepkowski S. Antisense intracellular adhesion molecule-1 (ICAM-1) oligodeoxynucleotide blocks allograft rejection in rat and monkey models [abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May 26-30: Dallas (TX), 172
180. Kato Y, Yamataka A, Yagita H. et al. Specific acceptance of fetal bowel allograft in mice after combined treatment with anti-interccllulur adhesion molecule-1 and leukocyte function-associated antigen-1 antibodies. Ann Surg 1996; 223: 94-100
181. Kawauchi M, Isobe M, Nakajima J. et al. Prolongation of allograft survival with anti-LFA-1-b monoclonal antibody, A primate heart transplantation study [abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May; Dallas (TX), 211
182. Hourmant M, Le Mauff B, Le Meur Y. et al. Administration of an anti-CD11a monoclonal antibody in recipients of kidney transplantation: a pilot study, Transplantation 1994; 58: 377-80
183. Hibberd AD, Grochowicz PM, Clark D. et al. Castanospermine an oligosaccharide processing inhibitor reduces membrane expression of adhesion molecules and prolongs heart allograft survival in rats [abstract], XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona. 62
184. Miller G, Hochman P, Meier W. et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993; 178: 211-22
185. Kaplon R, Hochman P, Michler R. et al. Short course single agent therapy with an LFA-3-lgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996; 61: 356-63
186. Nizet Y, Xu L, Bazin H. et al. Immunosuppression and CD2 down-modulation by a rat anti-human CD2 mAh [abstract]. XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 478
187. Biddeson W, Shaw S. Possible involvement of the OKT4 molecule in T-cell recognition of class II HLA antigens. Diagn Immunol 1983: 1: 112-6
188. Wood K, Pearson T, Darby C. et al. CD4: a potential target molecule for immunosuppressive therapy and tolerance induction, Transplant Rev 1991; 5: 150-64
189. Reinherz E, Kung P, Goldstein G. et al. Separation of functional subsets of human T cells by a monoclonal antibody, Proc Natl Acad Sci USA 1979; 76: 4061-5
190. Wilde D, Marrack P, Kappler J. et al. Evidence implicating L3T4 in class II MHC antigen reactivity: monoclonal antibody GK1.5 (anti L3T4a) blocks class II MHC antigen specific proliferation, release of lymphokines and binding by cloned murine helper T lymphocyte lines. J Immunol 1983; 131: 2178-83
191. Doyle C, Strominger J, Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 1487; 330: 256-9
192. Bank I, Chess L. Perturbation of the T4 molecule transmits a negative signal to T cells. J Exp Med 1985; 162: 1294-1303
193. Saizawa K, Rojo J, Juneway CM, Evidence for physical association of CD4 and CD3: T-cell receptor. Nature 1987; 328: 260-3
194. Woodcock J, Wofsy D, Eriksson E. et al. Rejection of skin grafts and generation of cytoloxic T cells by mice depleted of L3T4 cells. Transplantation 1986; 42: 636-42
195. Madsen J, Peugh W, Wood K. et al. The effect of anti-L3T4 monoclonal antibody treatment on first-set rejection of murine cardiac allografts, Transplantation 1987; 44: 849-52
196. Cosimi A, Burton R, Kung P. et al. Evaluation in primate renal allograft recipients of monoclonal antibody to human T-cell subclasses. Transplant Proc 1981; 13: 499-503
197. Jonker M, Neuhaus P, Zucker C. et al. OKT4 and OKT4A antibody treatment as immunosuppression for kidney transplantation in rhesus monkeys. Transplantation 1985; 39: 247-53
198. Herbert J, Roser B, Strategies of monoclonul antibody therapy that induce permanent tolerance of organ transplants |abstract], Transplantation 1988; 46: 128A
199. Cobbold S, Jayesuriya A, Prospeno T. et al. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature 1984; 112: 548-51
200. Qin S, Wise M, Cobbold S. et al. Induction of tolerance in peripheral T cells with monoclonal antibodies. EurJ Immunol 1990; 20: 2737-45
201. Darby C, Morris P, Wood K. Evidence that long-term cardiac allograft survival induced by anti-CD4 monoclonal antibody does not require depletion of CD4+ T cells. Transplantation 1992; 54: 483-90
202. Lehmann M, Sternkopf F, Metz. F. et al. Induction of long-term survival of rat skin allografts by a novel, highly efficient antiCD4 monoclonal antibody. Transplantation 1992; 54: 959-62
203. Trowbridge I, Thomas M. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 1994; 12: 85-116
204. Lazarovits A, Poppema S, Zhang Z. et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 1996; 380: 717-20
205. Linsley P, Ledbetter J. The role of CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11: 191-212
206. Aruffo A, Seed B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc Natl Acad Sci USA 1987; 84: 8573-7
207. Gross J, Callas E, Allison J. Identification and distribution of the costimulatory receptor CD28 in the mouse. J Immunol 1992; 144: 380-8
208. Linsley P, Brady W, Urnes M. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-9
209. June C, Bluestone J, Nadler L. et al. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321-31
210. Linsley P, Clarck E, Ledbetter J. T cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1, Proc Natl Acad Sci USA 1990; 87: 5031-5
211. Shaw S, Cinther-Luce G, Quinones R. et al. Two antigen-independent adhesion pathways used by cytotoxic T-cell clones. Nature 1986; 323: 262-4
212. Kuchroo V, Das D, Brown J. et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-18
213. Shahinian A, Pfeffer K, Lee K. et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261: 609-12
214. Green J, Noel P, Sperling A, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994; 1: 501-8
215. Waterhouse P, Penninger J, Timms E. et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995; 270: 932-3
216. Su B, Jacinto H, Hibi M. et al. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 1994; 77: 727-30
217. Lenschow D, Zeng Y, Thistlethwaite J, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789-92
218. Turka L, Linsley P. Lin H. et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo, Proc Natl Acad Sci USA 1992; 89: 11102-5
219. Linsley P, Wallace P, Johnson J. et al. Immunosuppression in vivo by a soluble form on the CTLA-4 T-cell activation antigen. Science 1992; 257: 792-5
220. Perico N, Imberti O, Bontempelli M. et al. Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4Ig. Kidney Int 1995; 47: 241-6
221. Lenschow DJ, Zeng Y, Thistlethwaite JR. et al. Long-term survival of xenogencic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789-92
222. Lin H, Bolling SF, Linsley PS. et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993; 178: 1801-6
223. Pearson TC, Alexander DZ, Winn KJ. et al. Transplantation tolerance induced by CTLA4Ig. Transplantation 1994; 57: 1701-6
224. Sayegh MS, Akalin E, Hancock WW. et al. CD28-B7 blockade after allogenic challenge in vivo inhibits Thl cytokines but spares Th2. J Exp Med 1995; 181: 1869-74
225. Greenstein SM, Sun S, Schenchne RS. et al. Immunomodulation with intrathymic injection of donor splenocytes followed by CTLA4Ig therapy prolongs small intestinal allograft survival. Transplant Proc 1997; 29: 1065-6
226. Steurer W, Nickerson P, Steiger J. et al. Pretrentment of islet cell allografts with CTLA4/Fc is able to induce long-term graft acceptance in mice [abstract]. J Am Soc Nephrol 1994; 5: 990
227. Sayegh M, Turka L. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 1995; 6: 1143-50
228. Volk H, Graser M, Risch K. et al. Synergism of CTLA4-Ig and anti-CD4 monoclonal antibody treatment in rat transplant models [abstract] XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 240
229. Sayegh M, Akalin E, Hancock W, et al. Blocking the CD28-B7 costimulatory T cell activation pathway with CTLA4Ig prevents chronic rejection in the Lew to F344 vascularized rat cardiac allograft model. J Clin Invest 1994; 5: 990-5
230. Hale D, Gottschalk R, Fukuzaki T. et al. Prolongation of skin allografts survival in mice treated with CTLA-4Ig in combination with rapamycin. cyclosporine or ALS/BM [abstract]. XVI International Congress of the Transplantation Society, 1996 Aug 25-30; Barcelona, 477
231. Alexander D, Pearson T, Ritchie S, et al. An analysis of costimulatory pathways in alloimmune responses |abstract|. In: American Society of Transplant Physicians 15th Annual Meeting; 1996 May 26-30; Dallas (TX), 118
232. Verburg R, Chandraker A, Vella J. et al. Differential effects of CTLA4Ig versus a mutant form of CTLA4Ig which hinds only B7-1 on the alloimmune responses in vitro and in vivo [abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May 26-30; Dallas (TX). 118
233. Larsen C, Alexander D, Hollenbaugh D. et al CD40-gp.19 interactions play a critical role during allograft rejection, Transplantation 1996; 61: 4-9
234. Foy TM, Durie FH, Noelle RJ. The expansive role of CD40 and its ligand. gp.19, in immunity. Sem Immunol 1994; 6: 259-66
235. Parker DC, Greiner DL, Phillips NE. Survival of mouse pancreatic islet allografts in recipients treated with allogencic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 1995; 92: 9560-4
236. Larsen CP, Elwood ET, Alexander DZ. et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381; 434-8
237. Caux C, Massacrier C, Vandervliet B. et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180: 1263-72
238. Grewal IS, Flavell RA. A central role of CD40 ligand in the regulation of CD4*T-cell responses, Immunol Today 1996; 17: 410-4
239. Morikawa M, Shorthouse R, Suto M. et al. A novel inhibitor of NK-κB and AP-1 transcription factors in T cells suppresses host vs graft alloreactivity in vivo [abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May 26-30; Dallas (TX). 172
240. Heaney M, Golde D. Soluble cytokine receptors. Blood 1996; 87: 847-57
241. Piccotti J, Bishop D. IL-12 receptor antagonism induces differential IFNG production by CD4+ and CD8+T cells [abstract]. American Society of Transplant Physicians 15th Annual Meeting: 1996 May 26-30: Dallas (TX). 129
242. Kupiec-Weglinski J, Diamanstein T, Tilney N. Interleukin 2 receptor-targeted therapy - rationale and applications in organ transplantation. Transplantation 1988; 46: 785-92
243. Carl S, Wiesel M, Daniel V. et al. Rescue therapy with inlerleukin-2 receptor antibody in high risk kidney transplant patients: a 3 year follow-up study [abstract]. XVI International Congress of the Transplantation Society; 1996 Aug 25-30: Barcelona. 194
244. Neuhaus P, Sechstein W, Blumhardt G. et al. Comparison of quadruple immunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation 1993; 55: 1320-7
245. Amlot P, Rawlings E, Fernando O. et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Trunsplantation 1995; 60: 748-56
246. Bartlett R, Dimitrijevic M, Zielinski T, et al. Leflunomide (HWA 486). a novel immunomodulating compound for the treatment of auto immune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32: 10-21
247. Cao W, Kao P, Aoki Y. et al. Induction of TGFb1 and reduction of IL-2 production: a novel mechanism of action of the immunosuppressive drug, leflunomide |abstract]. XVI International Congress of the Transplantation Society; 1996 Aug 25-30: Barcelona, 441
248. Chong A, Finnegan A, Jiang X. et al. Lellunomide, a novel immunosuppressive agent: the mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361-6
249. Kuchle C, Thoenes O, Langer K. et al. Prevention of kidney and skin graft rejection in rats by leflunomide. a new immunomodulating agent. Transplant Proc 1991; 23: 1083-6
250. D'Silva M, Candinas D, Achilleos O. et al. The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. Transplantation 1995; 60: 430-7
251. Williams J, Xiao F, Foster P. et al. Leflunomide in experimental transplantation - control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 1223-31
252. McChesney L, Xiao F, Sankary H. et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717-22
253. Xiao F, Chong A, Foster P. Leflunomide on acute rejection in hamster to rat cardiac xenografts [abstract]. 2nd International Congress on Xenotransplantation; 1993 Jun 10-13; Cambridge, 160
254. Wright JR, Kearns H, MacDonald AS. Leflunomide prolongs fish-to-mouse islet xenograft survival in BALB/C mice [abstract]. 2nd International Congress on Xenotransplantation; 1993 Jun 10-13: Cambridge, 146
255. Ulrichs K, Kaitschick J, Bartlett R. et al. Suppression of natural xenophile antibodies with the novel immunomodulating drug leflunomide. Transplant Proc 1992; 24: 718-9
256. Shen J, Xiao F, Liu W. et al. Reversal and stabilization of chronic cardiac allografl rejection in rats by leflunomide and cyclosporine [abstract], XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 522
257. Chen SF, Ruben RL, Dexter DL. Mechanism of action of the novel anticancer agent 6-fluoro-2-(2′-fluoro-1, Ix'-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res 1986; 46: 5014-8
258. Lakaschus G, Loffer M. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to brequinar sodium (NSD 368390) in vitro. Biochem Pharm 1992; 43: 1025-30
259. Cramer DV, Chapman FA, Jaffee BD. et al. The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat. Transplantation 1992; 53: 303-8
260. Takeuchi T, linuma H, Kunimoto S. et al. A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot (Tokyo) 1981; 34: 1619-21
261. Makino M, Fujiwara M, Watanabe H. et al. Immunosuppressive activities of deoxyspergualin: II. The effects on the antibody responses. Immunopharmacology 1987; 14: 115-22
262. Fujii H, Takada T, Nemoto K. et al. In vitro immunosuppressive properties of spergualins to murine T cell response. J Antibiot (Tokyo) 1989; 42: 788-94
263. Nadler S, Tepper M, Schacter B. et al. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992; 258: 484-6
264. Ito S, Ueno M, Arakawa M. et al. Therapeutic effect of 15-deoxyspergualin on the progression of lupus nephritis in MLR mice: I. Immunopathological analyses. Clin Exp Immunol 1990;81:446-53
265. Mochizuki M, Kawashima H. Effects of FK506. 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. Autoimmunity 1990; 8: 37-41
266. Schorlemmer H, Seiler F. 15-Deoxyspergualin (15-DOS) for therapy in an animal model of multiple sclerosis (MS): disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE). Agents Actions 1991; 34: 156-60
267. 13P nuclear magnetic resonance spectography and its effect on rat heart transplantation. Transplantation 1988; 46: 669-72
268. Kato H, Ohkochi N, Orii T, et al. Effectiveness of 15-deoxyspergualin on steroid resistant acute rejection in living related liver transplantation [abstract]. XVI International Congress of the Transplantation Society; 1996 Aug 25-30: Barcelona, 186
269. Davis M, Bjorkman P. T cell receptor genes and T-cell recognition. Nature 1988; 334: 395-402
270. Bjorkman P, Saper M, Samraoui B. et al. Structure of the human class I histocompatibility antigen. HLA-A2. Nature 1987; 329: 506-12
271. Bjorkman P, Saper M, Samraoui B. et al. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512-8
272. Chen W, McCluskey J, Rodda S. et al. Changes at peptide residues buried in the major histocompatibility complex class I binding cleft influence T cell recognition: a possible role for indirect conformational alterations in the MHC class I or bound peptide in determining T cell recognition. J Exp Med 1993; 177: 869-73
273. Schumacher T, Heemels M, Neefjes J. et al. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 1990; 62: 563-7
274. Moretta L, Ciccone E, Moretta A. et al. Allorecognition by NK cells: non-self or no self? Immunol Today 1992; 13: 300-6
275. Parham P, Clayberger C, Zorn S. et al. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the a: domain of HLA-A2. Nature 1987; 325: 625-8
276. Clayberger C, Parham P, Rothbard J. et al. HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes. Nature 1987; 330: 763-5
277. Olson C, Williams L, McLaughin T. et al. Creation of H-2 class I epitopes using synthetic peptides recognition by alloreactive cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1989; 86: 1031-5
278. Schneck J, Maloy W, Coligan J. et al. Inhibition of an allospecific T cell hybridoma by soluble class I proteins and peptides: estimation of the affinity of a T cell receptor for MHC. Cell 1989; 56: 47-55
279. Zavazava N, Hausmann R, Muller-Richholtz W. Inhibition of anti-HLA-B7 alloreactive CTL by affinity-purified soluble HLA. Transplantation 1991; 51: 838-42
280. Clayberger C, Lyu S, Pouletty P. et al. Peptides corresponding to T-cell receptor-HLA contact regions inhibit class l-restricted immune response. Transplant Proc 1993; 25: 477-8
281. Nisco S, Vriens P, Hoyt G. et al. Induction of allograft tolerance by an HLA class I derived peptide and cyclosporine A. J Immunol 1994; 152: 3786-92
282. Moretta A, Vitale M, Bottino C. et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class l-protected cells in NK clones displying different specificities. J Exp Med 1993; 178: 597-604
283. Cuturi M-C, Josien R, Douillard P. et al. Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a.a. 75-84) from the al helix of the first domain of HLA-B7 01. Transplantation 1995; 59: 661-9
284. Buelow R, Veyron P, Clayberger C. et al. Prolongation of skin allograft survival in mice following administration of allotrap. Transplantation 1995; 59: 455-60
285. Meuer S, Hodgdon J, Hussey R. et al. Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones. J Exp Med 1983; 158: 988-93
286. Smith C, Williams G, Kingston R. et al. Anybodies to CD/T-cell receptor complex induce death by apoplosis in immuture T cells in thymic cultures. Nature 1989; 337: 181-4
287. Thatte U, Uahanukar S, Apoptosis: clinical relevance und pharmacological manipulation. Drugs 1997 Oct; 54 (4): 511-32
288. Bursch W, Kleine L., Tenniswood M. The biochemistry of cell death by apoptosis. Biochem Cell Biol 1990; 68: 1071-4
289. + T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature 1991; 349: 245-8
290. Russell J, While C, Loh D. et al. Receptor-stimulated death pathway is opened by antigen in mature T cells. Proc Nutl Acad Sci USA 1991; 88: 2151-5
291. Ucker D, Meyers S, Ohermiller P. Activation-driven T cell death: II. Quantitative differences alone distinguish stimuli triggering nontransformed T cell proliferation or death. J Immunol 1992; 149: 1583-92
292. Wesselhorg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 1993; 150: 4338-45
293. Fujitn T, Yoneta M, Hirose R. Simple compounds, 2-alkyl-2-amino-1.3.-propanediols, have potent immunosuppressive activity. Bioorg Med Chem 1995; 5: 847-52
294. Adachi K, Kohara T, Nakano N. Design, synthesis, and structure-activity relationship of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg Med Chem 1995; 5: 853-8
295. Suzuki S, Enosawa S, Kakefuda T. et al. A novel immunosuppressant. FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 1996; 61: 200-5
296. Lynch D, Ramsdell F, Alderson M, Fas and Fasl. in the homeostatic regulation of immune responses, Immunol Today 1995; 16: 569-74
297. Miyawaki T, Uehara T, Nibu R. et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood, J Immunol 1992; 149: 3753-8
298. Klns C, Debatin K-M, Jonker RR. et al. Activation interferes with the APO-1 pathway in mature human T cells. Int Immunol 1993; 5: 625-30
299. Owen-Schaub L, Yonehara S, Crump WI. et al. DNA fragmentation and cell death is selectivety triggered in activated human lymphocytes by Fas antigen engagement, Cell Immunol 1992; 140: 197-205
300. Lau H, Yu M, Fontana A. et al. Prevention of islet allograft rejection with engineered myoblasts expressing FusL in mice. Science 1996; 273: 109-12
301. Csete ME, Drazan KE, Van Bree M. et al. Adenovirus-mediated gene transfer in the transplant setting, Transplantation 1994; 57: 1502-7
302. Shaked A, Csete ME, Drazan KE. Adenovirus-mediated gene transfer in the transplant setting, Transplantation 1994; 57: 1508-11
303. Chen SJ, Wilson JM, Muller DWM. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. Circulation 1994; 89: 1922-8
304. Guzman RJ, Lemarchand P, Crystal RG. et al. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res 1993; 73: 1202-7
305. Drazan KE, Wu L, Shen XD. et al. Adenovirus-mediated gene transfer in the transplant setting, Transplantation 1995; 59: 670-3
306. Wang J, Ma Y, Knechtle SJ. Adenovirus-mediated gene transfer into rat cardiac allografts. Transplantation 1996; 61: 1726-9
307. Miller N, Vile R. Targeted vectors for gene therapy. KASEB J 1995; 9: 190-9
308. Curiel DT, Wagner E. Cotten M. et al. High-efficiency gene transfer mediated by adenovirus coupled to DNA-polylysine complexes. Hum Gene Ther 1992; 3: 147-54
309. Michael SI, Huang CH, Romer MU. et al. Binding-incompetent adenovirus facilitates molecular conjugate-mediated gene transfer by the receptor-mediated endocytosis pathway, J Biol Chem 1993; 268: 6866-9
310. Zeigler ST, Kerby JD, Curiel DT. et al. Molecular eonjugate-mediated gene transfer into isolated human kidneys. Transplantation 1996; 61: 812-7
311. Qin L. Chavin KD. Ding Y. et al. Multiple vectors effectively achieve gene transfer in a murine cardiac transplantation model. Transplantation 1995; 59: 809-16
312. Qin L, Ding Y, Robson N. et al. Adenovirus-mediated gene transfer of viral interleukin 10 inhibits the immune response 10 both alloantigen and adenoviral antigen [abstract], American Society of Transplant Physicians 15th Annual Meeting: 1996 May 26-30; Dallas (TX), 110
313. Gordillo G, Xia D, Bergese S. et al. IL-4 gene therapy in murine cardiac graft recipients |abstract], XVI International Congress of the Transplantation Society; 1996 Aug 25-30: Barcelona. 426
314. Olthoff K, Gelman A, Shen X. et al. Alloimmune inhibition mediated by local modulation of liver grafts with adenoviral vector encoding CTLA4Ig [abstract]. American Society of Transplant Physicians 15th Annual Meeting; 1996 May 26-30: Dallas (TX). 173
315. Olthoff K, Shen X-D, Gelman A. et al. Adenovirus-mediated gene transfer of CTLA4Ig to liver allografts results in prolonged survival and local T cell anergy [abstract], XVI International Congress of the Transplantation Society: 1996 Aug 25-30; Barcelona. 83
316. Shaked A, Olthoff K, Chen X-D. et al. Tolerance to a second donor-matched allograft following local immune modulation using transfer of sequences encoding CTLA4Ig [abstract]. XVI International Congress of the Transplantation Society: 1996 Aug 25-30; Barcelona, 71
317. Karlsson S, Correll PH, Xu L., Gene transfer and hone marrow transplantation with special reference to Gaucher's disease. Bone Marrow Transplant 1993; 11 Suppl. 1: 124-7
318. Golsorkhi AA, Min JK, Shaked A. et al. Prolongation of islet allograft survival by vector-mediated gene transfer of TGF-b and IL-10 [abstract], XVI International Congress of the Transplantation Society; 1996 Aug 25-30: Barcelona, 375
319. Deng S, Ketchum RJ, Kucher T. et al. Adenovirus transfection of canine islet xenografts with immunosuppressive cytokine genes abrogates primary non-function and prolongs graft survival [abstract], XVI International Congress of the Transplantation Soeiely, 1996 Aug 25-30; Barcelona. 378
320. Negita M, Hayashi S, Yokoyama I. et al. Protective effect of human superoxide dismutase cDNA transfection in the prevention of cold preservation injury [abstract|. XVI International Congress of the Transplantation Society; 1996 Aug 25-30; Barcelona, 496